Study of ZEN003694 for Squamous Cell Lung Cancer with NSD3 Mutation
This study is looking into ZEN003694, a drug that blocks certain proteins (BET inhibitors), as a potential treatment for advanced squamous cell lung cancer. Researchers believe that by blocking these proteins, ZEN003694 might slow or stop cancer growth, especially in people whose cancer has a specific change in the NSD3 gene. You might be able to join if you have squamous cell lung cancer that has come back or spread, and your cancer has this NSD3 gene mutation. The study aims to see how many participants respond to the treatment over two years. The current status of this study is unclear, and it plans to enroll 13 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 13 participants.
- What's involved
- You would take ZEN003694 by mouth (po) at 60mg once daily (qd) for 5 days on and 2 days off, in cycles of 21 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure how well the treatment works for up to 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05607108
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Recruiting
PHASE2Ages 18+InterventionalTreatmentMemorial Sloan Kettering Cancer CenterInvestigator-initiated
~13 participants
Updated 2026-03-11 on ClinicalTrials.gov
What's tested:ZEN003694
At a glance
Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
overall response rate (ORR)
Measured over 2 years
Conditions
Where it's being run
7 sites across 2 statesNew York4
New Jersey3
Study leadership
- Paul Paik, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically-confirmed squamous cell lung cancer
Recurrent or metastatic disease
Patients with previously treated asymptomatic brain metastases requiring no more than 10mg prednisone (or equivalent) are allowed. Patients with asymptomatic brain metastases ≤ 1cm not requiring more than 10mg prednisone (or equivalent) are allowed.
Received prior first-line therapy: platinum-based chemotherapy and immunotherapy, given either concurrently or sequentially
Eastern Cooperative Oncology Group (ECOG) PS 0-2
Evidence of NSD3 gain or amplification by NGS, including but not limited to evidence of 8p11 gain or amplification as determined by MSK IMPACT or MSK ACCESS, or a commercially available molecular assay that is FDA authorized. Note: ctDNA testing, including but not limited to MSK ACCESS and Guardant and Foundation
Adequate laboratory parameters at Screening including:
Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
Platelet count ≥ 100,000/mm\^3
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.0 ULN (≤ 5 x ULN if liver metastases are present)
Total bilirubin ≤ 1.25 x ULN
Calculated or measured eGFR ≥ 40 ml/min or serum creatinine ≤ 1.5 x ULN
Prothrombin time (PT), international normalized ratio (INR) and partial thromboplastin time (PTT) \< 1.5 x ULN
Ability to swallow capsules
Use of corticosteroids is allowed up to a daily dose of 10 mg prednisone or equivalent provided that the dose has been stable for at least 2 weeks prior to the start of ZEN003694 dosing and will remain stable during ZEN003694 treatment.
Females or males age ≥ 18 years (at time of signing informed consent)
Female subjects may be enrolled if they are not of childbearing potential, permanently sterile or who are post-menopausal defined as no menses for at least 1 year without an alternative medical cause and FSH levels in the post-menopausal range. Female subjects of childbearing potential may be enrolled if they consistently and correctly use a highly effective form of contraception. Highly effective forms of contraception include: combined (estrogen and progestogen hormonal contraceptives (oral, intravaginal, transdermal) associated with inhibition of ovulation; progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence. Female subjects should not donate eggs from the time point of study drug administration until at least 7 months thereafter.
Males with partners of childbearing potential may be enrolled if they use a condom when having sex with a pregnant woman or with a non-pregnant female of childbearing potential from 21 days before the first dose of study drug through 4 months after the last dose of study drug, and males should not donate sperm from the time point of study drug administration until at least 4 months thereafter.
Females of childbearing potential must have a negative serum or urine pregnancy test before the first dose of study drugs and must agree to pregnancy tests during the study.
Females may not be breast-feeding at the first dose of study drugs, during study participation or through 7 months after the last dose of study drugs
Exclusion
Have previously received an investigational BET inhibitor
Have received prior systemic anti-cancer therapy or investigational therapy within 2 weeks or five half-lives, whichever is shorter, prior to the first dose of study drug
Radiation therapy within 2 weeks of first dose of study drug
Currently receiving medications known to be strong inducers or inhibitors of CYP3A4 and substrates of CYP1A2 with a narrow therapeutic window. Strong inducers and inhibitors of CYP3A4 and CYP1A2 substrates with narrow therapeutic ranges must be discontinued at least 7 days prior to the first administration of study drug.
Left ventricular ejection fraction less than the lower of 50% or the lower limit of institution's normal range
QTcF interval \> 470 msec
Known impaired cardiac function or clinically significant cardiac disease such as uncontrolled supraventricular arrhythmia, ventricular arrhythmia requiring therapy, or uncontrolled congestive heart failure (New York Heart Association functional class III or IV)
Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug
Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, or any other condition that could compromise safety or the patient's participation in the study
Other known active cancer requiring therapy at time of study entry
Historically positive (screening tests not required) for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections. HBV positivity defined by positive hepatitis B surface antigen (HBsAg). HCV positivity defined as positive HCV viral load.
Major surgery other than diagnostic surgery, dental surgery or stenting within 4 weeks prior to the first administration of study drug
History of congenital or other deficiency in platelet function, or any known inherent or acquired coagulopathy, including current anticoagulation therapy (except for low-dose warfarin for port patency)
Current or anticipated use within 7 days prior to the first administration of study drug, or during the study, of strong P-gp inhibitors.
Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed. Note: except for subjects on anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator.
What this trial measures
- overall response rate (ORR)2 years
Response to ZEN003694 will be determined using the sum unidimensional measurements of the target lesions present on the scan. Unidimensional measurement rules will adhere to RECIST 1.1 guidelines.(6) Classification of response will be categorized by RECIST 1.1 (CR, PR, SD, PD).